NASDAQ

DSGN

Design Therapeutics, Inc.
$10.64CS band Mixed

☾After Hours +0.00 (+0.01%)Nov 4, 7:59 PM ET

At close $10.63 · +0.29 (+2.84%)

Mkt Cap
$665.5M
Volume
262.3K
52W High
$17.25
52W Low
$6.16
PE Ratio
—
Avg Vol
479.5K
As of 11/3/26
Div Yield
—
Beta
1.12
As of 11/3/26

Company

Headquarters
Carlsbad, CA
Employees
55 (2026)
Listed
Mar 26, 2021
Exchange
Nasdaq
Website
designtx.com
SEC industry
Pharmaceutical Preparations
Cylvex sector
Health Care · Pharmaceuticals

Pharmaceuticals

  • Market cap #155 of 430
  • P/B #120 of 396

Ranked highest first among stocks Cylvex covers.

  1. LLYEli Lilly and Company$1.26T+0.60%
  2. JNJJohnson & Johnson$665.3B+3.83%
  3. ABBVAbbVie Inc$520.9B+3.07%
  4. MRKMerck & Co Inc$370.9B+3.91%
  5. NVSNovartis AG$311.6B+3.60%
All Pharmaceuticals ›

Financial summary

Related companies

About

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

From company filings and market data · Not investment advice

Price data

Day Low $10.31Day High $10.79
52W Low $6.1652W High $17.25
Open
$10.67
Prev Close
$10.34
Volume
262.3K
Avg Vol (30D)
463.6K

From daily bars

Financials

Consensus estimates

The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.